A Study Comparing Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis
Official Title
M16-046: A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis
Purpose
The purpose of this study is to compare the effectiveness and safety of upadacitinib (ABT-494) versus dupilumab for the treatment of adult subjects (18-75 years of age) with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Could this study be right for you?
- Subject must have chronic Atopic Dermatitis (AD) with onset at least 3 years prior to study participation
- Subject must have > or = 10% body surface area involvement of atopic dermatitis
- Subject must have had inadequate response to topical corticosteroids or topical calcineurin inhibitors within the past 6 months
- OR documented systemic treatment for AD within the past 6 months
- OR for whom topical treatments are otherwise medically inadvisable
- No prior exposure to any JAK inhibitor (e.g., ruxolitinib, tofacitinib, baricitinib, upadacitinib, PF-04965842, and filgotinib)
- No prior exposure to dupilumab